Your browser is no longer supported. Please, upgrade your browser.
Settings
PGNX Progenics Pharmaceuticals, Inc. daily Stock Chart
PGNX [NASD]
Progenics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own6.46% Shs Outstand81.48M Perf Week27.14%
Market Cap423.70M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float78.37M Perf Month15.30%
Income-73.00M PEG- EPS next Q-0.19 Inst Own78.10% Short Float12.48% Perf Quarter20.09%
Sales16.70M P/S25.37 EPS this Y-11.60% Inst Trans-7.95% Short Ratio10.42 Perf Half Y30.33%
Book/sh0.99 P/B5.25 EPS next Y91.90% ROA-44.30% Target Price9.50 Perf Year-39.75%
Cash/sh1.35 P/C3.87 EPS next 5Y- ROE-80.60% 52W Range3.62 - 9.42 Perf YTD23.81%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-44.40% 52W High-44.78% Beta2.47
Dividend %- Quick Ratio4.80 Sales past 5Y14.70% Gross Margin- 52W Low43.65% ATR0.24
Employees79 Current Ratio4.80 Sales Q/Q34.40% Oper. Margin- RSI (14)66.38 Volatility5.98% 5.32%
OptionableYes Debt/Eq0.52 EPS Q/Q-19.70% Profit Margin- Rel Volume2.02 Prev Close5.20
ShortableYes LT Debt/Eq0.45 EarningsMay 09 BMO Payout- Avg Volume938.58K Price5.20
Recom1.50 SMA2018.80% SMA5010.28% SMA2004.89% Volume0 Change0.00%
Dec-07-18Initiated Credit Suisse Outperform $6.50
Sep-14-18Downgrade Needham Strong Buy → Buy $16 → $12
Aug-01-18Reiterated Needham Strong Buy $14 → $16
Feb-06-17Upgrade Needham Buy → Strong Buy $11 → $14
Oct-27-16Initiated Aegis Capital Buy
Oct-23-15Upgrade Jefferies Hold → Buy
Aug-07-15Reiterated Needham Buy $9 → $11
Aug-06-15Reiterated Brean Capital Buy $11 → $14
Feb-03-14Upgrade Needham Hold → Buy $8
Aug-30-12Initiated Stifel Nicolaus Hold
Jul-30-12Downgrade Needham Buy → Hold
Feb-10-11Upgrade Brean Murray Hold → Buy $13
Oct-14-09Downgrade Needham Buy → Hold
May-12-09Reiterated RBC Capital Mkts Outperform $14 → $12
Mar-16-09Reiterated RBC Capital Mkts Outperform $21 → $14
Mar-16-09Downgrade Oppenheimer Outperform → Perform
Mar-16-09Downgrade Brean Murray Buy → Hold
Mar-12-09Initiated FTN Equity Capital Neutral
Aug-11-08Reiterated RBC Capital Mkts Outperform $19 → $21
Jul-02-08Downgrade Friedman Billings Mkt Perform → Underperform $9 → $12
Jun-24-19 08:30AM  Independent Readers Using Progenics PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI GlobeNewswire
08:00AM  Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velans Latest Inaccurate Claims GlobeNewswire
Jun-20-19 05:21PM  Velan Releases Detailed Presentation on Progenics Pharmaceuticals PR Newswire
08:30AM  Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors GlobeNewswire
07:30AM  Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims PR Newswire
Jun-19-19 12:05PM  Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%? Simply Wall St.
08:30AM  Progenics to Mail Letter to Shareholders GlobeNewswire
Jun-18-19 09:05AM  Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan GlobeNewswire +6.41%
Jun-17-19 08:30AM  Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements PR Newswire +6.85%
Jun-13-19 05:00PM  Progenics to Mail Letter to Shareholders GlobeNewswire
08:30AM  Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer GlobeNewswire
Jun-11-19 08:30AM  Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation PR Newswire
Jun-06-19 07:45AM  Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting GlobeNewswire
Jun-04-19 08:30AM  Velan Responds to Progenics Pharmaceuticals' Misleading Statements PR Newswire +6.85%
Jun-03-19 08:30AM  Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma GlobeNewswire
08:00AM  Progenics Pharmaceuticals Mails Letter to Shareholders GlobeNewswire
May-30-19 08:30AM  Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-23-19 08:30AM  Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting GlobeNewswire
May-22-19 08:30AM  Velan Files Definitive Proxy Materials in Connection with Progenics Pharmaceuticals 2019 Annual Meeting of Stockholders PR Newswire
May-19-19 11:59PM  Edited Transcript of PGNX earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-14-19 08:30AM  Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404 GlobeNewswire
May-13-19 08:30AM  Velan Implores for Improved Transparency and Real Change at Progenics Pharmaceuticals Following Q1 2019 Earnings Call PR Newswire -5.50%
May-10-19 02:24PM  Progenics Pharmaceuticals (PGNX) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 09:05AM  Progenics (PGNX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:53AM  Progenics: 1Q Earnings Snapshot Associated Press
07:45AM  Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update GlobeNewswire
May-08-19 02:30PM  Velan Calls for Increased Transparency at Progenics Pharmaceuticals During Q1 Earnings Call PR Newswire
May-07-19 04:15PM  Progenics Pharmaceuticals Comments on Velan Capitals Preliminary Proxy Statement GlobeNewswire
May-06-19 04:15PM  Progenics Pharmaceuticals Issues Statement Regarding Velan Capital GlobeNewswire
08:30AM  Velan Delivers Letter to the Board of Progenics Pharmaceuticals PR Newswire
08:30AM  Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics PyL Imaging Agent GlobeNewswire
May-02-19 08:30AM  Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9 GlobeNewswire
May-01-19 10:32AM  Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline Zacks
Apr-24-19 08:30AM  Results from Clinical Trial Show Progenics PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% of Patients GlobeNewswire
Apr-12-19 08:00PM  Investor Altiva Wants to Repopulate Progenics Board Barrons.com
08:41AM  These 3 Biotech Stocks Are Moving Closer to Profitability TheStreet.com
Apr-11-19 08:17AM  How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year? Simply Wall St. +8.53%
Apr-03-19 05:05PM  Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
05:00PM  Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting GlobeNewswire
Mar-18-19 12:26PM  Edited Transcript of PGNX earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
10:00AM  My Post-Earnings Assessment of 2 Biotech Stocks TheStreet.com
Mar-14-19 09:10AM  Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates Zacks
08:18AM  Progenics: 4Q Earnings Snapshot Associated Press
07:47AM  The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering Benzinga
07:45AM  Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update GlobeNewswire
07:40AM  Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent GlobeNewswire
Mar-11-19 08:30AM  Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA® (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting GlobeNewswire
Mar-07-19 08:30AM  Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14 GlobeNewswire
Feb-20-19 09:12AM  3 Small Biotechs to Watch as Earnings Season Winds Down TheStreet.com
Feb-11-19 08:30AM  Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility GlobeNewswire
Jan-22-19 07:45AM  Market Trends Toward New Normal in Agilent Technologies, Xilinx, Interpublic Group of Companies, Progenics Pharmaceuticals, Flexsteel Industries, and USA Truck Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-03-19 04:45PM  Steven Cohen Storms Into Progenics Pharmaceuticals GuruFocus.com
01:30AM  Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL GlobeNewswire
Jan-02-19 08:30AM  Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer GlobeNewswire
Dec-12-18 09:06AM  Here Are 3 Small-Cap Names for Biotech Investors to Consider TheStreet.com +5.96%
Dec-11-18 02:35PM  What Did Progenics Pharmaceuticals, Inc.s (NASDAQ:PGNX) CEO Take Home Last Year? Simply Wall St. +8.29%
Dec-08-18 07:50PM  Should You Buy NanoString Technologies Inc (NSTG)? Insider Monkey
Dec-05-18 05:09PM  Is Noodles & Co (NDLS) A Good Stock To Buy? Insider Monkey
Dec-03-18 08:30AM  Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer GlobeNewswire
Nov-28-18 07:30AM  Research Report Identifies Capstone Turbine, LivePerson, Diamondback Energy, Presidio, Pretium Resources, and Progenics Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-19-18 04:30PM  Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting GlobeNewswire
Nov-08-18 05:38PM  Edited Transcript of PGNX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
09:55AM  Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:49AM  Progenics: 3Q Earnings Snapshot Associated Press
07:30AM  Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update GlobeNewswire
Nov-06-18 08:00AM  Progenics Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 08:00AM  Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8 GlobeNewswire
Oct-18-18 08:25AM  Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.48%
Oct-12-18 07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
Oct-11-18 04:01PM  Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA GlobeNewswire
Oct-09-18 08:30AM  Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine GlobeNewswire
Oct-08-18 06:28PM  Generic-Drugs Stock Outlook: No Respite from Pricing Issues Zacks
Oct-05-18 09:52AM  Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results' Benzinga
07:30AM  Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer GlobeNewswire
Sep-26-18 03:48PM  Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 32.98% Discount Simply Wall St.
Sep-25-18 08:30AM  Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-20-18 10:43AM  Progenics Pharma's Stock Down on Dismal Phase III Study Data Zacks
Sep-17-18 06:00AM  Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma GlobeNewswire
Sep-14-18 08:00AM  Todays Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals ACCESSWIRE -6.34%
Sep-13-18 04:28PM  Qualcomm and Tailored Brands rise; Kroger stumbles Associated Press -17.88%
12:40PM  Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today Motley Fool
08:42AM  The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals ACCESSWIRE
Sep-12-18 05:21PM  After-hours buzz: PVTL, PGNX & more CNBC
04:49PM  Progenics stock falls on missed study endpoint MarketWatch
04:01PM  Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404 GlobeNewswire
Aug-27-18 07:55AM  Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-07-18 10:12PM  Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-01-18 09:01AM  Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial Benzinga
Jul-31-18 07:17PM  Progenics: 2Q Earnings Snapshot Associated Press
04:30PM  Following Azedras Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update GlobeNewswire
11:40AM  FDA approves first non-surgical treatment for 2 rare cancers American City Business Journals
09:01AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma ACCESSWIRE
07:40AM  3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona InvestorPlace
Jul-30-18 09:46PM  Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma GlobeNewswire +8.49%
04:04PM  FDA approves Progenics' treatment for rare adrenal gland tumors Reuters
03:35PM  FDA approves Progenics' treatment for two rare tumors Reuters
01:46PM  The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO Benzinga
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.